NEW YORK (GenomeWeb News) – The plaintiff in a lawsuit that accused Sequenom of capping the price of its MaterniT21 Plus non-invasive prenatal test in order to drive up its adoption has dropped her case.

The plaintiff Bette Borenstein voluntarily dismissed her lawsuit earlier this week in US District Court for the Southern District of California five months after initiating the litigation. No reason was provided in court papers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.